JP2022517742A5 - - Google Patents
Info
- Publication number
- JP2022517742A5 JP2022517742A5 JP2021538378A JP2021538378A JP2022517742A5 JP 2022517742 A5 JP2022517742 A5 JP 2022517742A5 JP 2021538378 A JP2021538378 A JP 2021538378A JP 2021538378 A JP2021538378 A JP 2021538378A JP 2022517742 A5 JP2022517742 A5 JP 2022517742A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- strand comprises
- antisense
- sequence described
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024067819A JP2024105308A (ja) | 2018-12-28 | 2024-04-18 | Hmgb1発現を阻害するための組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862786287P | 2018-12-28 | 2018-12-28 | |
| US62/786,287 | 2018-12-28 | ||
| US201862787038P | 2018-12-31 | 2018-12-31 | |
| US62/787,038 | 2018-12-31 | ||
| US201962788111P | 2019-01-03 | 2019-01-03 | |
| US62/788,111 | 2019-01-03 | ||
| PCT/US2019/067883 WO2020139764A1 (en) | 2018-12-28 | 2019-12-20 | Compositions and methods for inhibiting hmgb1 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024067819A Division JP2024105308A (ja) | 2018-12-28 | 2024-04-18 | Hmgb1発現を阻害するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022517742A JP2022517742A (ja) | 2022-03-10 |
| JP2022517742A5 true JP2022517742A5 (cg-RX-API-DMAC7.html) | 2023-02-24 |
Family
ID=71128894
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538378A Pending JP2022517742A (ja) | 2018-12-28 | 2019-12-20 | Hmgb1発現を阻害するための組成物及び方法 |
| JP2024067819A Withdrawn JP2024105308A (ja) | 2018-12-28 | 2024-04-18 | Hmgb1発現を阻害するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024067819A Withdrawn JP2024105308A (ja) | 2018-12-28 | 2024-04-18 | Hmgb1発現を阻害するための組成物及び方法 |
Country Status (13)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10675295B2 (en) | 2017-06-29 | 2020-06-09 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting HMGB1 expression |
| TW202400790A (zh) * | 2022-04-26 | 2024-01-01 | 大陸商上海拓界生物醫藥科技有限公司 | 氘代化學修飾和包含其的寡核苷酸 |
| TWI868755B (zh) * | 2022-06-24 | 2025-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 抑制跨膜絲胺酸蛋白酶6(tmprss6)表現的組成物及方法 |
| CN117264954A (zh) * | 2022-09-20 | 2023-12-22 | 北京福元医药股份有限公司 | 用于抑制hmgb1基因表达的双链核糖核酸及其修饰物、缀合物和用途 |
| WO2024233864A2 (en) * | 2023-05-10 | 2024-11-14 | Dicerna Pharmaceuticals, Inc. | Galnac-conjugated rnai oligonucleotides |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080311122A1 (en) * | 2005-11-28 | 2008-12-18 | Medimmune, Llc | Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof |
| WO2007150071A1 (en) * | 2006-06-23 | 2007-12-27 | Myriad Genetics, Inc. | Gene amplifications and deletions |
| WO2011007876A1 (ja) * | 2009-07-16 | 2011-01-20 | Necソフト株式会社 | Hmgb1結合核酸分子およびその用途 |
| EP2617426B1 (en) * | 2010-09-17 | 2016-08-10 | Japan Science and Technology Agency | Inhibitor of hmgb protein-mediated immune response activation |
| WO2012177639A2 (en) * | 2011-06-22 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Bioprocessing and bioproduction using avian cell lines |
| US10351854B2 (en) * | 2014-10-10 | 2019-07-16 | Dicerna Pharmaceuticals, Inc. | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
| EP3865576A1 (en) * | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| WO2017079227A1 (en) * | 2015-11-05 | 2017-05-11 | University Of Connecticut | Compositions and methods for the treatment of liver fibrosis |
| WO2018045317A1 (en) * | 2016-09-02 | 2018-03-08 | Dicerna Pharmaceuticals, Inc. | 4'-phosphate analogs and oligonucleotides comprising the same |
| US10675295B2 (en) * | 2017-06-29 | 2020-06-09 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting HMGB1 expression |
| WO2019126097A1 (en) * | 2017-12-18 | 2019-06-27 | Alnylam Pharmaceuticals, Inc. | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof |
-
2019
- 2019-12-20 IL IL284327A patent/IL284327B2/en unknown
- 2019-12-20 IL IL313425A patent/IL313425A/en unknown
- 2019-12-20 WO PCT/US2019/067883 patent/WO2020139764A1/en not_active Ceased
- 2019-12-20 BR BR112021012516-7A patent/BR112021012516A2/pt not_active Application Discontinuation
- 2019-12-20 CA CA3124664A patent/CA3124664A1/en active Pending
- 2019-12-20 AU AU2019417585A patent/AU2019417585A1/en not_active Withdrawn
- 2019-12-20 MX MX2021007855A patent/MX2021007855A/es unknown
- 2019-12-20 CN CN201980093263.2A patent/CN113874025A/zh not_active Withdrawn
- 2019-12-20 EP EP19902219.5A patent/EP3883581A4/en not_active Withdrawn
- 2019-12-20 JP JP2021538378A patent/JP2022517742A/ja active Pending
- 2019-12-20 SG SG11202106857VA patent/SG11202106857VA/en unknown
- 2019-12-20 US US17/309,860 patent/US20220072024A1/en not_active Abandoned
- 2019-12-20 KR KR1020217023455A patent/KR20210126004A/ko not_active Withdrawn
-
2021
- 2021-06-25 CL CL2021001718A patent/CL2021001718A1/es unknown
-
2023
- 2023-10-05 CL CL2023002984A patent/CL2023002984A1/es unknown
-
2024
- 2024-04-18 JP JP2024067819A patent/JP2024105308A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113164509B (zh) | 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法 | |
| TWI823866B (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| CN113748208A (zh) | 用于抑制中枢神经系统中的基因表达的组合物和方法 | |
| TWI924663B (zh) | 用於抑制PNPLA3表現之RNAi劑、其醫藥組成物及使用方法 | |
| CA3153026A1 (en) | Chemical modifications of small interfering rna with minimal fluorine content | |
| AU2022203361A1 (en) | Compositions and methods for modulating RNA | |
| CN110832077A (zh) | 用于抑制α-ENaC表达的RNAi剂及使用方法 | |
| TW202130809A (zh) | 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法 | |
| JP2024514880A (ja) | Pnpla3発現を調節するための組成物及び方法 | |
| WO2023245061A2 (en) | Lipid conjugates for the delivery of therapeutic agents to cns tissue | |
| EP4335859A1 (en) | Method for designing oligonucleotide having reduced central toxicity | |
| BR112021012516A2 (pt) | Composições e métodos para inibir a expressão de hmgb1 | |
| WO2025113592A1 (zh) | 一种抑制补体系统基因表达的rna抑制剂及其应用 | |
| US11634715B2 (en) | Methods and compositions for treating bile duct paucity-associated conditions | |
| TW202340471A (zh) | 用於抑制冠狀病毒(CoV)病毒基因體之RNAi藥劑、其組合物及使用方法 | |
| JP2022520653A5 (cg-RX-API-DMAC7.html) | ||
| TW202444904A (zh) | 用於抑制粒線體醯胺肟還原組分1(MARC1)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| EP1437408A1 (en) | Novel antisense oligonucleotide derivatives against hepatitis c virus | |
| EP4704858A1 (en) | Sugar modified oligonucleotides and uses thereof | |
| TW202503056A (zh) | 用於抑制補體因子B (CFB)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| EA049851B1 (ru) | РНКи-АГЕНТЫ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ PNPLA3, ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ |